Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pretargeting: general principles; October 10-12, 1996

D A Goodwin1, C F Meares

  • 1Nuclear Medicine Service, Veterans Affairs Palo Alto Health Care System, California 94304, USA.

Cancer
|December 24, 1997
PubMed
Summary

Pretargeting techniques enhance tumor uptake of radioactive yttrium-90 (90Y) by using a specific antibody conjugate. This method minimizes radiation exposure to healthy tissues, improving radioimmunotherapy safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancement of skin penetration of nonsteroidal anti-inflammatory drugs from extemporaneously compounded topical-gel formulations.

International journal of pharmaceutical compounding·2013
Same author

The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex.

Journal of the American Chemical Society·2011
Same author

Diffusion-enhanced lanthanide energy transfer studies of protein prosthetic groups.

Biophysical journal·2009
Same author

Pathological implications of iNOS expression in central white matter: an ex vivo study of optic nerves from rats with experimental allergic encephalomyelitis.

The European journal of neuroscience·2005
Same author

Advances in pretargeting biotechnology.

Biotechnology advances·2003
Same author

Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve.

Neuroscience·2002

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunotherapy

Background:

  • Monoclonal antibody (MoAb) radioimmunotherapy faces challenges due to slow tumor clearance and high radiation burden on normal tissues, particularly bone marrow.
  • Therapeutic radionuclides like yttrium-90 (90Y) have long biologic half-lives, exacerbating toxicity when unbound radioactivity remains in circulation.
  • Pretargeting strategies offer a potential solution to improve tumor targeting and reduce off-target radiation exposure.

Purpose of the Study:

  • To evaluate the efficacy of pretargeting techniques in achieving high tumor concentrations of 90Y while minimizing background radioactivity.
  • To assess the impact of pretargeting on normal tissue toxicity, specifically bone marrow irradiation.

Main Methods:

  • Utilizing pretargeting systems, such as biotin/avidin or hapten/antibody, with a long-circulating conjugate and a diffusible effector molecule.
  • Employing various ligand/receptor systems, including DNA/DNA and prodrug/enzyme, for targeted delivery.
  • Measuring the biologic half-life and tumor/blood concentrations of radiolabeled conjugates in a mouse tumor model.

Main Results:

  • Pretargeting achieved fast tumor uptake and slow clearance kinetics, ideal for therapeutic applications.
  • A bivalent 88Y JANUS tetraazacyclododecanetetraacetic acid hapten exhibited a biologic half-life of approximately 24 hours in a mouse model.
  • The therapeutic ratio was significantly improved (approximately 20/1) compared to directly labeled MoAb (2-3/1), with only 5.5% of the injected dose remaining at 24 hours, 23% of which was tumor-localized.

Conclusions:

  • Pretargeting techniques show promise for delivering tumoricidal doses of 90Y.
  • This approach may allow for effective radioimmunotherapy without causing severe bone marrow irradiation.

Related Experiment Videos